Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia

In conclusion, although our data do not support the repurposing of lorcaserin, acamprosate or ganaxolone per se for LID, we demonstrate value of an in silico approach to identify candidate molecules which, in combination with an in vivo screen, can facilitate clinical development decisions. The present study adds to a growing literature in support of this paradigm shifting approach in the repurposing pipeline.PMID:38412888 | DOI:10.1016/j.neuropharm.2024.109880

Source: Neuropharmacology - February 27, 2024 Category: Drugs & Pharmacology Authors: Tom H Johnston Alix M B Lacoste Paula Ravenscroft Jin Su Sahar Tamadon Mahtab Seifi Anthony E Lang Susan H Fox Jonathan M Brotchie Naomi P Visanji Source Type: research